This study looks at how a higher dose of a medicine called HD nusinersen affects people with Spinal Muscular Atrophy (SMA) who have already been treated with another medicine, risdiplam. SMA is a disease that makes muscles weak and hard to control. The study checks if HD nusinersen improves muscle movement and if it's safe for people to use.
To be part of the study, participants must show genetic signs of SMA, start showing symptoms after 6 months of age, and be between 15 and 50 years old. They should weigh more than 20 kg and have used risdiplam for a specific time. They must stop taking risdiplam and be ready to start HD nusinersen.
Participants cannot join if they have a major illness, infections, or need certain medical devices or treatments. They also cannot be pregnant or breastfeeding.
- Study Duration: Check how long the study lasts and how many visits are needed.
- Safety: Consider any risks or side effects of switching medications.
- Eligibility: Make sure you meet all the requirements to join the study.